Lin YS, Zhang X, Wang C, et al. - Given that radioiodine refractory differentiated thyroid cancer (RAIR-DTC) has poor prognosis and limited treatment options, researchers reported the long-term results of phase 2 clinical trial of apatinib, an anti-angiogenic tyrosine kinase inhibitor, for RAIR-DTC. Data reported that the objective response rate was 80% and the disease control rate was 95%. It was noted that the overall median PFS was 18.4 months and median OS was 51.6 months. Patients with BRAF<sup>V600E mutation had a longer median PFS vs patients with BRAF wild-type. Palmar-plantar erythrodysaesthesia syndrome (19/20), proteinuria (18/20) and hypertension (16/20) were among the most common adverse events. Apatinib was found to have long-term efficacy and a tolerable safety profile in this long-term evaluation, making it a promising treatment choice for progressive RAIR-DTC.